{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:49:26Z","timestamp":1794487766620,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01124-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:02:50Z","timestamp":1772186570000},"page":"608-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial"],"prefix":"10.1038","volume":"7","author":[{"given":"Yang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-5133","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-1724","authenticated-orcid":false,"given":"Siyuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libing","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-3783","authenticated-orcid":false,"given":"Xuanwen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-0910","authenticated-orcid":false,"given":"Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5479-899X","authenticated-orcid":false,"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Villarejo","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1500-9991","authenticated-orcid":false,"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9849-347X","authenticated-orcid":false,"given":"Weijia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"1124_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1124_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1124_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1124_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li, D. et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci. Adv. 9, eadg9721 (2023).","journal-title":"Sci. Adv."},{"key":"1124_CR5","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J. Clin. Oncol. 42, 2565\u20132577 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1124_CR6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1007\/s10637-020-00955-w","volume":"38","author":"ZW Han","year":"2020","unstructured":"Han, Z. W. et al. The old CEACAMs find their new role in tumor immunotherapy. Invest. New Drugs 38, 1888\u20131898 (2020).","journal-title":"Invest. New Drugs"},{"key":"1124_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-017-2045-4","volume":"66","author":"A Holzinger","year":"2017","unstructured":"Holzinger, A. & Abken, H. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target. Cancer Immunol. Immunother. 66, 1505\u20131507 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"1124_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9010021","volume":"9","author":"L Lakemeyer","year":"2021","unstructured":"Lakemeyer, L. et al. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. Diseases 9, 21 (2021).","journal-title":"Diseases"},{"key":"1124_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol. Ther. 25, 1248\u20131258 (2017).","journal-title":"Mol. Ther."},{"key":"1124_CR10","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz, S. C. et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. 21, 3149\u20133159 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1124_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite, F. C. et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol. Immunother. 66, 1425\u20131436 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"1124_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","volume":"1","author":"Y Ye","year":"2019","unstructured":"Ye, Y. et al. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat. Metab. 1, 431\u2013444 (2019).","journal-title":"Nat. Metab."},{"key":"1124_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal. Transduct. Target. Ther. 8, 70 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1124_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu, X. et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 84, 84\u2013100 (2024).","journal-title":"Cancer Res."},{"key":"1124_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti, P. et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep. Med. 2, 100227 (2021).","journal-title":"Cell Rep. Med."},{"key":"1124_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002755","volume":"9","author":"H He","year":"2021","unstructured":"He, H. et al. Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. J Immunother. Cancer 9, e002755 (2021).","journal-title":"J Immunother. Cancer"},{"key":"1124_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella, S. M. et al. Locoregional delivery of CAR-T cells in the clinic. Pharmacol. Res. 182, 106329 (2022).","journal-title":"Pharmacol. Res."},{"key":"1124_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","volume":"40","author":"L Cherkassky","year":"2022","unstructured":"Cherkassky, L., Hou, Z., Amador-Molina, A. & Adusumilli, P. S. Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell 40, 569\u2013574 (2022).","journal-title":"Cancer Cell"},{"key":"1124_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz, S. C. et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther 23, 142\u2013148 (2016).","journal-title":"Cancer Gene Ther"},{"key":"1124_CR20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544\u20131552 (2021).","journal-title":"Nat. Med."},{"key":"1124_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","volume":"19","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian, V. et al. Advances in the management of peritoneal malignancies. Nat. Rev. Clin. Oncol. 19, 698\u2013718 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1124_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jcyt.2023.10.007","volume":"26","author":"S Qian","year":"2024","unstructured":"Qian, S. et al. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study. Cytotherapy 26, 113\u2013125 (2024).","journal-title":"Cytotherapy"},{"key":"1124_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"1124_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00256-x","volume":"5","author":"J Wei","year":"2020","unstructured":"Wei, J. et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal. Transduct. Target. Ther. 5, 134 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1124_CR25","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"1124_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"1124_CR27","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1124_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41\u201353 (2023).","journal-title":"Lancet"},{"key":"1124_CR29","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li, J. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448\u20131454 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1124_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437\u20131448 (2018).","journal-title":"Lancet Oncol."},{"key":"1124_CR31","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan, A. et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int. J. Biol. Sci. 17, 3837\u20133849 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"1124_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","volume":"27","author":"SC Katz","year":"2020","unstructured":"Katz, S. C. et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther. 27, 341\u2013355 (2020).","journal-title":"Cancer Gene Ther."},{"key":"1124_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001097","volume":"8","author":"SC Katz","year":"2020","unstructured":"Katz, S. C. et al. HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J. Immunother. Cancer 8, e001097 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1124_CR34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov"},{"key":"1124_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1124_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.ejso.2008.03.010","volume":"34","author":"D Go\u00e9r\u00e9","year":"2008","unstructured":"Go\u00e9r\u00e9, D. et al. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur. J. Surg. Oncol. 34, 1335\u20131339 (2008).","journal-title":"Eur. J. Surg. Oncol."},{"key":"1124_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1634\/theoncologist.2019-0282","volume":"25","author":"C Ursem","year":"2020","unstructured":"Ursem, C. et al. Clinicopathologic characteristics and impact of oophorectomy for ovarian metastases from colorectal cancer. Oncologist 25, 564\u2013571 (2020).","journal-title":"Oncologist"},{"key":"1124_CR38","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1124_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Brit. Med. J. 340, c332 (2010).","journal-title":"Brit. Med. J."},{"key":"1124_CR40","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1124_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01124-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01124-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01124-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:02:14Z","timestamp":1777471334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01124-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01124-3","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.Y., L.W., Y.L., Y. Zhang, Q.Z., J.S., X.H., C.Y. and C.Q. are employees of Chongqing Precision Biotech. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}